Q4 2025 earnings call highlights: record sales, Skyrizi/Rinvoq momentum, 2026 guidance ($67B) and risks—read key takeaways.

AbbVie Inc. forecast 2026 profits above Wall Street’s expectations, though investors saw vulnerabilities in some of the ...

Feb 4 (Reuters) - AbbVie forecast 2026 profit above ‌Wall ​Street estimates on Wednesday ‌after posting a fourth-quarter results beat, fueled by strong demand ​for newer immunology drugs Skyrizi and ...

Kenvue Inc. (NYSE: KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February ...

AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...

Investors who are risk-averse and looking for stability, reliability, and income should definitely opt for AbbVie. It's the ...

Injectable dermal products have become some of the most sought-after cosmetic treatments. But behind every injection lies a ...

Why going the extra mile might make you feel good — plus, how extreme weather events could increase the burden of malaria in ...

New research suggests pain is not a simple signal of injury but a process that unfolds across nerves, spinal cord, and brain.

CVS Health outlined its efforts to decrease prior authorizations, reduce hospital readmissions and emergency room visits and ...

Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...